BioSpace News Archive

Drug Development

Antibody-Drug Conjugates, Lung Cancer Late-Breaker to Take Center Stage at ASCO

ADCs from BioNTech, Daiichi Sankyo and Merck are the subject of high-profile abstracts featured at the oncology meeting, along with Merck’s late-breaking Phase III non-small cell lung cancer data.

June 2, 2023
·
5 min read
·
Greg Slabodkin
Drug Development

The Promise and Perils of Antisense Therapies in CNS Diseases

The recent approval of Biogen’s Qalsody in SOD1–ALS highlighted the potential of ASOs in CNS diseases, while recent failures make it clear there is still work to be done.

June 2, 2023
·
5 min read
·
Heather McKenzie
Drug Development

Pfizer’s Antibiotic Combo Clears Phase III, Shows Promise Against Multidrug Resistance

The company’s aztreonam-avibactam matched the cure rate of a meropenem-based regimen in patients with drug-resistant infections.

June 2, 2023
·
3 min read
·
Tristan Manalac
Business

Coherus to Offer 85% Discount for its Humira Biosimilar

The company’s Humira biosimilar Yusimry will launch in July with a $995 list price. Mark Cuban’s online pharmacy will sell it at a list price of $569.27 plus fees.

June 2, 2023
·
2 min read
·
Tristan Manalac
Drug Development

ASCO: Novartis’ Kisqali Prevents Breast Cancer Return in Phase III Trial

The Swiss pharma’s CDK4/6 inhibitor reduced risk for recurrence by 25% when added to the standard-of-care endocrine therapy, inviting comparisons to Lilly’s Verzenio.

June 2, 2023
·
2 min read
·
Kate Goodwin
Drug Development

ASCO Highlights

Follow news from the American Society of Clinical Oncology 2023 annual meeting—BioSpace will be tracking key updates here throughout the conference.

June 2, 2023
·
6 min read
·
BioSpace Editorial Staff
Drug Development

ASCO: Keytruda Scores Phase III NSCLC Win, Outperforms AstraZeneca’s Imfinzi

Combined with chemotherapy, Keytruda in KEYSTONE-671 significantly improved EFS and reduced the risk of disease recurrence, progression or death by 42%, beating Imfinzi’s EFS in the AEGEAN trial.

June 2, 2023
·
2 min read
·
Rosemary Scott
Grail Expands Blood Test to Symptomatic Patients, Aims to Revolutionize Cancer Diagnosis

June 2, 2023
·
1 min read
Policy

CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals, Inc. announced that the Chinese National Medical Products Administration has approved CAN108 to be marketed for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

June 2, 2023
·
8 min read
BioForest

Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics

Evotec SE announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.

June 2, 2023
·
7 min read